Supreme Court’s Drug Patent Ruling Could Expand Use Of Expert Testimony
This article was originally published in The Gray Sheet
Executive Summary
High court rules Federal Circuit should have granted deference to district court’s decision on meaning of a patent claim for a multiple sclerosis drug.